US drugmaker starts phase 3 trial for COVID-19 antibody treatment
Washington(WA): American pharmaceutical company Eli Lilly & Firm has declared the begin of its stage three trial to research whether 1 of its experimental COVID-19 antibody treatments could prevent the infection infection in locals & employees in long-term care facilities. LY-CoV555, the lead antibody from Lilly’s collaboration with Canadian biotech AbCellera, is a neutralizing antibody …